微信扫码关注“小狗文献”

即刻体验更多权益

文献多,下载快,翻译准

首页 > 医学词汇大全 > CHA2DS2--VASc score
CHA2DS2--VASc score

心血管

关键词心血管 临床研究术语 心颤评分系统

词汇介绍

拓展阅读

解析

score 英 /skɔː/ 美 /skɔ/ 

释义   n. 分数;二十;配乐;刻痕; vt. 获得;评价;划线,刻划;把…记下; vi. 得分;记分;刻痕

例句   Add up your score on each question. 

把每道题的分数加起来。

概述

背景欧洲心脏病协会(ESC)心房颤动处理指南(2010年版)提出了CHA2DS2-VASc [congestive heart failure, hypertension, age≥75y(doubled), diabetes mellitus, stroke(doubled)- vascular disease, age 65-74 and sex category(female)]评分系统。CHA2DS2-VASc进一步拓展了CHADS2的功能,其作为非瓣膜性房颤患者发生

Predictive performance of the CHA2DS2-VASc rule in atrial fibrillation: a systematic review and meta-analysis复制标题

CHA2DS2-VASc规则对心房颤动预测作用的系统评价和meta分析

发表时间:2017-04-04

影响因子:4.7

作者: S.VAN DOORN

期刊:J. Thromb. Haemost.

Indications — Anticoagulant therapy is effective in reducing the risk of systemic embolization in patients with atrial fibrillation (AF). Anticoagulation with warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban reduces this risk by almost 70 percent, and should be considered for most AF patients. However, the use of anticoagulant therapy is also associated with an increased risk of major bleeding. While the benefit outweighs the risk in most patients, careful consideration of the risk-to-benefit ratio is necessary in those at relatively very low (CHA2DS2-VASc score of 0) and low risk (CHA2DS2-VASc score of 1).  Recommendations for anticoagulant therapy in patients with nonvalvular AF are as follows:For patients with a CHA2DS2-VASc score ≥2, we recommend chronic anticoagulation (Grade 1A);For male patients with a CHA2DS2-VASc score of 1, our authors and reviewers have differing approaches, with some recommending no antithrombotic therapy and some recommending oral anticoagulant therapy. The risk factor present may influence decision making. Age 65 to 74 years is a stronger risk factor than the other features conferring a CHA2DS2-VASc score of 1;For patients with a CHA2DS2-VASc of 0 or 1 in females, we suggest no anticoagulant therapy (Grade 2C). Patients who are particularly stroke averse and who are at low bleeding risk may reasonably choose anticoagulation.

译文

适应症 - 抗凝治疗可有效降低心房颤动(AF)患者全身栓塞的风险。华法林,达比加群,利伐沙班,阿哌沙班或依多沙班的抗凝治疗可将此风险降低近70%,对大多数房颤患者应予以考虑。然而,抗凝治疗的使用也与大出血的风险增加有关。虽然这种益处超过了大多数患者的风险,但在相对非常低(CHA2DS2-VASc评分为0)和低风险(CHA2DS2-VASc评分为1)的患者中,必须仔细考虑风险与效益比。非瓣膜性房颤患者的抗凝治疗建议如下:对于CHA2DS2-VASc评分≥2的患者,我们建议慢性抗凝(1A级);对于CHA2DS2-VASc评分为1的男性患者,我们的作者和评价者有不同的方法,一些建议没有抗血栓治疗,一些建议口服抗凝治疗。存在的风险因素可能会影响决策。年龄65至74岁是比CHA2DS2-VASc评分为1的其他特征更强的风险因素;对于女性CHA2DS2-VASc为0或1的患者,我们建议不进行抗凝治疗(2C级)。特别卒中厌恶且出血风险低的患者可合理选择抗凝治疗。